	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
S5-PMC2821652	PMC2821652	2/2010	S5-PMC2821652	"[""one measurement of adherence was obtained via pill counts remaining COMPARED to a NOVEL definition for adherence using Serum 25-Hydroxy-Vitamin D (25-Oh-d) levels (absolute change in 25(Oh)D over the study period and the subject's steady-state variation in their 25(Oh)d levels).""]"	[('ANOMALY_CURIOUS_FINDING', 68), ('FULL_UNKNOWN', 82)]	2	[('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_70487', '(-)-sanguinolignan C', 125, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_75393', 'Y-27632', 147, '25-OH-'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 263, '25(OH')]
S77-PMC2821652	PMC2821652	2/2010	S77-PMC2821652	"[""in developing a definition of adherence by Serum 25(Oh)D levels, SEVERAL ASSUMPTIONS were made a priori about WHAT types of PATTERNS of 25(Oh)D levels would be exhibited by adherent and nonadherent patients BASED ON CURRENT KNOWLEDGE about the Metabolism Of Vitamin D.\nassumption 1\nBASED ON KNOWN pharmacokinetics of Vitamin D [64], adherent patients' 25(Oh)D levels would be expected to rise over time, eventually reaching a steady state after 2 months of therapy; nonadherent patients' 25(Oh)D levels would be expected to be erratic and to exhibit variable PATTERNS that would differ significantly from adherent patients' 25(Oh)D levels over the same dosing interval.""]"	[('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('EXPLICIT_QUESTION', 110), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 207), ('PROBABLE_UNDERSTANDING', 207), ('SUPERFICIAL_RELATIONSHIP', 207), ('INCOMPLETE_EVIDENCE', 216), ('PROBABLE_UNDERSTANDING', 282), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 291), ('SUPERFICIAL_RELATIONSHIP', 559)]	12	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 142, 'D'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 244, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 317, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 325, 'D'), ('CHEBI_71657', 'versiconol acetate', 352, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 358, 'D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 488, '25'), ('PR_000011614', 'opioid growth factor receptor', 491, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 494, 'D'), ('CHEBI_71657', 'versiconol acetate', 624, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 624, '25(OH ... D')]
S95-PMC3004407	PMC3004407	12/2010	S95-PMC3004407	['the odds of Vitamin D deficiency (AS measured by 25(Oh)D concentration) did NOT APPEAR TO change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR odds of Vitamin D deficiency and insufficiency for a given race/ethnicity than women who had their 25(Oh)D concentrations measured earlier in Pregnancy ( p = .43).']	[('PROBABLE_UNDERSTANDING', 34), ('ANOMALY_CURIOUS_FINDING', 76), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 178)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 285, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 291, 'D'), ('GO_0007565', 'female pregnancy', 328, 'pregnancy')]
S130-PMC3004407	PMC3004407	12/2010	S130-PMC3004407	['women who reported taking a Prenatal Vitamin containing 400\u2009iu Vitamin D did not differ from those who did not in Vitamin D status as measured by 25(Oh)d.\nWHILE present in caucasian women, the greatest prevalence of deficiency was NOTED in those women of darker pigmentation, specifically, african-american and hispanic women.']	[('ANOMALY_CURIOUS_FINDING', 155), ('ANOMALY_CURIOUS_FINDING', 231)]	2	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 37, 'vitamin'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 146, '25(OH')]
S7-PMC3257641	PMC3257641	3/2010	S7-PMC3257641	['with regard to terminology, we use Vitamin D when referring to Cholecalciferol or Ergocalciferol (BUT ‘Vitamin D3’ or ‘Vitamin D2’ where reference is made specifically to only a single form of Calciferol); 25(Oh)D to refer to 25 Hydroxycalciferol (including both 25(Oh)D2And 25(Oh)d3), and 1,25(Oh)2D, the active form of the hormone, to include both 1,25(Oh)2D2And 1,25(Oh)2D3.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 98)]	1	"[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 63, 'cholecalciferol'), ('CHEBI_4910', 'etomidate', 82, 'ergocalciferol'), ('CHEBI_33279', 'vitamin D5', 103, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 103, 'vitamin D3'), ('CHEBI_28934', 'vitamin D2', 119, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 119, 'vitamin D2'), ('CHEBI_28623', 'campesterol', 193, 'calciferol'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('CHEBI_65819', 'eckol', 226, '25 hydroxycalciferol'), ('CHEBI_76948', 'ent-manool', 263, '25(OH)D2and'), ('CHEBI_63056', 'zinc cation', 275, '25(OH'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 292, '25(OH)2D'), ('CHEBI_76948', 'ent-manool', 352, '25(OH)2D2and'), ('CHEBI_73394', 'Ala-Ser', 367, '25(OH)2D3')]"
S187-PMC3347028	PMC3347028	3/2012	S187-PMC3347028	['results of two RECENT randomized controlled trials during Pregnancy\nin our RECENTLY completed nichd Vitamin D supplementation trial involving a diverse group of Pregnant women less than 16 weeks of Gestation, 4000 iu (100 μg) Vitamin D3/day was SUPERIOR to 400 (control)- or 2000 iu/day in achieving circulating 25(Oh)d of at least 40 ng/ml (100 nmol/l), the point at which 1,25(Oh)2D begins to be optimized (seefigure 2) [6].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 245)]	3	[('GO_0007565', 'female pregnancy', 58, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnant'), ('GO_0007565', 'female pregnancy', 198, 'gestation'), ('CHEBI_33279', 'vitamin D5', 226, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 226, 'vitamin D3'), ('CHEBI_63056', 'zinc cation', 312, '25(OH'), ('CHEBI_82784', 'PVP38-Ag NP', 374, '1,25(OH)2D')]
S87-PMC3355895	PMC3355895	1/2011	S87-PMC3355895	['FINDINGS from the avon longitudinal study of parents and children (sayers and tobias,2009) FURTHER REINFORCED the IMPORTANCE of maternal 25(Oh)-Vitamin D levels, DEMONSTRATING a positive ASSOCIATION between ambient ultraviolet b radiation in Pregnancy and offspring bmc at 9 years old.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 114), ('INCOMPLETE_EVIDENCE', 162), ('SUPERFICIAL_RELATIONSHIP', 187)]	6	[('CHEBI_63056', 'zinc cation', 137, '25(OH'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy')]
S160-PMC3356951	PMC3356951	4/2012	S160-PMC3356951	['synthetic analogs of Vitamin D\n\nmaxacalcitol (22-Oxacalcitriol or oct) is the FIRST analog FOUND to have a wider therapeutic window than 1,25(Oh)2d3.']	[('INCOMPLETE_EVIDENCE', 78), ('INCOMPLETE_EVIDENCE', 91)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_37090', '1-anthrol', 46, '22-oxacalcitriol'), ('CHEBI_63056', 'zinc cation', 139, '25(OH')]
S42-PMC3427192	PMC3427192	4/2012	S42-PMC3427192	['studies of Vitamin D status in school-age children with asthmaauthoryearn(% male)age (years)study designsampleoutcome measuresfindingsbrehm412009616 (60)8.7cross-sectionalmild-to-severe persistent asthmaasthma exacerbationsincreased 25(Oh)D ASSOCIATED with reduced hospitalization, reduced Anti-Inflammatory Medication use and reduced Airway hyperresponsivenessbrehm6920101024 (60)8.9prospective cohortmild-to-moderate persistent asthmahospitalization or emergency Department visitbaseline 25(Oh)D levels < 30 ng/ml ASSOCIATED with higher odds of hospitalization or emergency department over 4 ychinellato70201175 (60)9.6cross-sectionalwell-controlled and POORLY controlled asthmaspirometry, asthma controlpositive CORRELATIONS NOTED between 25(Oh)d and asthma controlchinellato71201145 (60)10cross-sectionalintermittent asthmalung function and Airway hyperresponsivenesslower Serum 25(Oh)D ASSOCIATED with decreased Lung function and increased Airway hyperresponsiveness with exercisefreishtat72201092 (63)11.1cross-sectionalafrican americans with and without asthmaphysician-diagnosed asthmadecreased 25(Oh)D in asthmatics vs. controlsmajak73201148 (67)11.5randomized, double-blind, parallel arm clinical trialnewly diagnosed asthmaasthma exacerbationsfewer exacerbations in children with Vitamin D3Supplementation added to inhaled Budesonidesearing742010100 (64)7cross-sectionalmoderate to severe persistent asthmacorticosteroid use and Airflow limitationdecreased 25(Oh)D ASSOCIATED with lower Lung function and higher Corticosteroid requirementsurashima752010217 (57)10.0randomized, double-blind clinical trialschoolchildren (allcomers), subgroup with physician-diagnosed asthmaasthma exacerbationsreduced risk of asthma exacerbations in the subgroup with asthma after Vitamin D3Supplementation\nother cross-sectional studies of Vitamin D status have also examined the ASSOCIATIONS between 25(Oh)D concentrations and asthma Control in school-age children.']	[('SUPERFICIAL_RELATIONSHIP', 241), ('SUPERFICIAL_RELATIONSHIP', 516), ('PROBLEM_COMPLICATION', 656), ('SUPERFICIAL_RELATIONSHIP', 715), ('ANOMALY_CURIOUS_FINDING', 728), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1476), ('SUPERFICIAL_RELATIONSHIP', 1873)]	8	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 233, '25(OH)D'), ('CHEBI_60426', 'dioleoyl phosphatidylglycerol', 290, 'anti-inflammatory medication'), ('UBERON_0001005', 'respiratory airway', 335, 'airway'), ('UBERON_0008247', 'tube foot', 465, 'department'), ('CHEBI_71657', 'versiconol acetate', 490, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 490, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 742, '25(OH'), ('UBERON_0001005', 'respiratory airway', 845, 'airway'), ('UBERON_0001977', 'blood serum', 877, 'serum'), ('CHEBI_71657', 'versiconol acetate', 883, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 885, '(OH ... D'), ('UBERON_0002048', 'lung', 917, 'lung'), ('UBERON_0001005', 'respiratory airway', 945, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1103, '25(OH)D'), ('CHEBI_52915', 'phosphatediyl group', 1291, 'vitamin D3supplementation'), ('CHEBI_72362', 'phosphatidylethanolamine 44:1-OH', 1334, 'budesonideSearing742010100'), ('UBERON_0001005', 'respiratory airway', 1440, 'airflow'), ('CHEBI_71657', 'versiconol acetate', 1468, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1468, '25(OH)D'), ('UBERON_0002048', 'lung', 1498, 'lung'), ('CHEBI_36916', 'cation', 1523, 'corticosteroid'), ('CHEBI_52915', 'phosphatediyl group', 1774, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 1833, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1894, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1900, 'D'), ('GO_0065007', 'biological regulation', 1928, 'control')]
S52-PMC3427192	PMC3427192	4/2012	S52-PMC3427192	['in these sub-analyses, Vitamin D3Supplementation was ASSOCIATED with a decreased risk of exacerbations compared with Placebo, with a relative risk of 0.17.75similarly, in a more RECENT randomized, double-blind 6-mo trial where 800 µg of inhaled Budesonide was administered daily to a small group of 48 children with asthma in the presence or absence of 500 iu/day of Vitamin D3, children receiving supplemental Vitamin D did not have a reduction in 25(Oh)D during the winter months and also had a reduced risk of asthma exacerbations triggered by acute Respiratory Viral infections.73these INITIAL FINDINGS SUGGEST that Vitamin D supplementation MAY have therapeutic benefit children with asthma, ALTHOUGH ADDITIONAL randomized, double-blind, placebo-controlled STUDIES ARE NEEDED.']	[('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 590), ('INCOMPLETE_EVIDENCE', 607), ('INCOMPLETE_EVIDENCE', 646), ('ANOMALY_CURIOUS_FINDING', 697), ('FUTURE_WORK', 706), ('FUTURE_WORK', 762)]	8	[('CHEBI_52915', 'phosphatediyl group', 23, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 23, 'vitamin D3supplementation'), ('CHEBI_26130', 'biological pigment', 117, 'placebo'), ('CHEBI_3219', 'bupropion', 245, 'budesonide'), ('CHEBI_33279', 'vitamin D5', 367, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 367, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 449, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 455, 'D'), ('UBERON_0001004', 'respiratory system', 553, 'respiratory'), ('NCBITaxon_1', 'root', 565, 'viral'), ('CHEBI_27300', 'vitamin D', 620, 'vitamin D')]
S244-PMC3641012	PMC3641012	4/2013	S244-PMC3641012	['we set a conservative upper limit of reference range for trial monitoring (2.60\xa0mmol/l), which was crossed by one participant in the Vitamin D group; HOWEVER, this was not logically attributable to Vitamin D toxicity based on normal repeat Serum calcium, normal ca:cr, and a 25(Oh)d that was well within the range considered to be non-hypercalcemic [37].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 150)]	1	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('UBERON_0001977', 'blood serum', 240, 'serum'), ('CHEBI_63056', 'zinc cation', 275, '25(OH')]
S10-PMC3668200	PMC3668200	5/2013	S10-PMC3668200	['HOWEVER, measuring 1,25-Oh2-D levels AS a PREDICTOR of Vitamin D status CAN LEAD TO ERRONEOUS CONCLUSIONS BECAUSE, compared with 25(Oh)D levels, 1,25-Oh2-D levels CAN be normal or EVEN elevated DESPITE Vitamin D deficiency due to secondary hyperparathyroidism.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 37), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 72), ('PROBABLE_UNDERSTANDING', 76), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('PROBLEM_COMPLICATION', 84), ('PROBLEM_COMPLICATION', 84), ('PROBABLE_UNDERSTANDING', 94), ('PROBABLE_UNDERSTANDING', 106), ('PROBLEM_COMPLICATION', 106), ('INCOMPLETE_EVIDENCE', 163), ('ANOMALY_CURIOUS_FINDING', 180), ('ANOMALY_CURIOUS_FINDING', 194)]	14	[('CHEBI_78731', '9(R)-HPETE', 21, '25-OH2-D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 129, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('CHEBI_78731', '9(R)-HPETE', 147, '25-OH2-D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
S16-PMC3702245	PMC3702245	6/2013	S16-PMC3702245	['high prevalence of low Vitamin D intake in Pregnancy\nthe Vitamin D status in Adults, including Pregnant women, is based currently on measurement of Serum 25(Oh)D concentrations, BUT WHAT constitutes the “normal” OR “optimal” level is CONTROVERSIAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('EXPLICIT_QUESTION', 182), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 212), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 234)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0007023', 'adult organism', 77, 'adults'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('UBERON_0001977', 'blood serum', 148, 'serum'), ('CHEBI_63056', 'zinc cation', 154, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 160, 'D')]
S27-PMC3702245	PMC3702245	6/2013	S27-PMC3702245	['high resolution three-dimensional ultrasound assessment in a study from the uk FOUND greater splaying of the distal Femoral Metaphysis in the fetus when maternal Serum 25(Oh)D was <50 nmol/l,60AND the authors SUGGESTED that this FINDING is SIMILAR TO radiologic features in Vitamin D-deficient rickets.']	[('INCOMPLETE_EVIDENCE', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 209), ('INCOMPLETE_EVIDENCE', 229), ('INCOMPLETE_EVIDENCE', 240)]	5	[('UBERON_0013751', 'metaphysis of radius', 116, 'femoral metaphysis'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_63056', 'zinc cation', 168, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 174, 'D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
S6-PMC3717170	PMC3717170	5/2013	S6-PMC3717170	['WHETHER Ingested OR synthesized, Vitamin D is transported to the Liver, where it is hydroxylated at position 25 to form 25-Hydroxyvitamin D (25(Oh)d2or 25(Oh)D3), the major circulating form of Vitamin D. next, 25(Oh)D3Is transported to the Kidney, where it is hydroxylated at position 1 by the enzyme Cyp27B1 to form 1,25-Dihydroxyvitamin D (1,25(Oh)2D3), the most active form of Vitamin D, which is then transported to target Tissues, where it functions like a Steroid, binding to the Vitamin D receptor (vdr).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('GO_0007631', 'feeding behavior', 8, 'ingested'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0002107', 'liver', 65, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 120, '25-hydroxyvitamin D'), ('CHEBI_63056', 'zinc cation', 141, '25(OH'), ('CHEBI_62946', 'ammonium sulfate', 152, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('CHEBI_71667', '2,3,4-saturated fatty acid', 210, '25(OH)D3is'), ('UBERON_0002113', 'kidney', 240, 'kidney'), ('PR_000006101', 'cytochrome P450 1A1', 301, 'CYP27B1'), ('CHEBI_67472', '15-epi-lupulin B', 317, '1,25-dihydroxyvitamin D'), ('CHEBI_72779', '11-trans-LTE4', 342, '1,25(OH)2D3'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('UBERON_0000479', 'tissue', 427, 'tissues'), ('CHEBI_35341', 'steroid', 462, 'steroid'), ('CHEBI_27300', 'vitamin D', 486, 'vitamin D')]
S68-PMC3717170	PMC3717170	5/2013	S68-PMC3717170	['Vitamin D during Pregnancy and Lactation\nVitamin D as a preprohormone has EFFECTS that extend beyond Calcium Metabolism and Homeostasis throughout Life but which are most vivid during Pregnancy when Vitamin D Metabolism is disengaged from its usual constraints.12at no other time during the Lifecycle is 25(Oh)D3Linked directly to 1,25(Oh)2d3production, the latter rising more than 2.5 times above nonpregnant levels.12this elevation of 1,25(oh)2d3likely serves the purpose of Immune Regulation, THOUGH there HAVE BEEN ONLY a FEW STUDIES that have evaluated the EFFECT of Vitamin D status on Immune function during Pregnancy to SUPPORT THIS HYPOTHESIS.']	[('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 484), ('ANOMALY_CURIOUS_FINDING', 496), ('INCOMPLETE_EVIDENCE', 509), ('INCOMPLETE_EVIDENCE', 519), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 562), ('INCOMPLETE_EVIDENCE', 628), ('QUESTION_ANSWERED_BY_THIS_WORK', 636), ('INCOMPLETE_EVIDENCE', 641)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('GO_0007595', 'lactation', 31, 'lactation'), ('CHEBI_28384', 'vitamin K', 41, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 41, 'Vitamin D'), ('GO_0018884', 'carbazole metabolic process', 101, 'calcium metabolism'), ('GO_0042592', 'homeostatic process', 124, 'homeostasis'), ('UBERON_0000104', 'life cycle', 147, 'life'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 199, 'vitamin D metabolism'), ('UBERON_0000104', 'life cycle', 291, 'lifecycle'), ('CHEBI_77914', '3-methylbut-1-ene', 304, '25(OH)D3linked'), ('CHEBI_63056', 'zinc cation', 333, '25(OH'), ('CHEBI_17996', 'chloride', 438, ','), ('GO_0002521', 'leukocyte differentiation', 477, 'immune regulation'), ('UBERON_0002405', 'immune system', 477, 'immune'), ('CHEBI_27300', 'vitamin D', 572, 'vitamin D'), ('UBERON_0002405', 'immune system', 592, 'immune'), ('GO_0007565', 'female pregnancy', 615, 'pregnancy')]
S33-PMC3827489	PMC3827489	10/2013	S33-PMC3827489	['IN LINE WITH THESE data, a study FOCUSING on adolescents aged 12-13 years REPORTED that 98.9% of boys and 100% of girls showed Vitamin D insufficiency or deficiency; 5.3% had 25(Oh)D insufficiency (20.0-29.9 ng/ml), 94.2% had deficient concentrations (<20.0 ng/ml), and ONLY 1 boy (1.1%) had OPTIMAL concentrations of 25(Oh)d6).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('INCOMPLETE_EVIDENCE', 74), ('ANOMALY_CURIOUS_FINDING', 270), ('INCOMPLETE_EVIDENCE', 270), ('IMPORTANT_CONSIDERATION', 292)]	7	[('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 175, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 318, '25(OH')]
S62-PMC3873449	PMC3873449	12/2013	S62-PMC3873449	['ALTHOUGH there HAS BEEN DEBATE over WHICH level of Serum 25(Oh)D REFLECTS optimum Vitamin D status, it is GENERALLY ACCEPTED that Serum 25(Oh)d level of < 30ng/ml(75nmol/l) is the cut-off value for insufficiency [15-17], which is ASSOCIATED with maximal suppression of Parathyroid hormone [18].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('EXPLICIT_QUESTION', 36), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 106), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 230)]	9	[('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001977', 'blood serum', 130, 'serum'), ('CHEBI_63056', 'zinc cation', 136, '25(OH'), ('UBERON_0001132', 'parathyroid gland', 269, 'parathyroid')]
S2393-PMC4113768	PMC4113768	7/2014	S2393-PMC4113768	['background: we performed a systematic review TO EXPLORE WHETHER (1) low maternal circulating 25(Oh)-Vitamin D (25(Oh)D) during Pregnancy is ASSOCIATED with impairment of offspring health; and (2) maternal supplementation with Vitamin D in Pregnancy MIGHT ameliorate these EFFECTS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 140), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 272)]	5	[('CHEBI_63056', 'zinc cation', 93, '25(OH'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 111, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]
S2637-PMC4113768	PMC4113768	7/2014	S2637-PMC4113768	['; inskip, h.m.; cooper, c.; harvey, n.c.\nbackground: maternal 25-Hydroxy-Vitamin D (25(Oh)d) status in Pregnancy HAS BEEN ASSOCIATED with offspring Bone Development and adiposity.']	[('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 122)]	2	[('CHEBI_70487', '(-)-sanguinolignan C', 62, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 84, '25(OH'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0048539', 'bone marrow development', 148, 'bone development')]
S2773-PMC4113768	PMC4113768	7/2014	S2773-PMC4113768	['conclusions: the free and bio-available forms of 25(Oh)D MAY BE a more INFORMATIVE measure of Vitamin D status than total 25(Oh)d. adjustment for dbp phenotype MAY improve this FURTHER.']	[('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 71), ('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 177), ('INCOMPLETE_EVIDENCE', 177)]	5	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 122, '25(OH')]
S3136-PMC4113768	PMC4113768	7/2014	S3136-PMC4113768	['DEPENDING ON the cutoff chosen, dietary intakes of Vitamin D MAY OR MAY NOT provide sufficient IMPACT upon Vitamin D status, in improving levels of 25(Oh)d. purpose: we SOUGHT TO EXAMINE WHETHER a supplemental dose of 10 mcg (400 iu) as found in fortified foods OR as a supplement, has a measurable IMPACT on Vitamin D status, as defined by improving status from below to above 50 nmol/l, or from less than 30 nmol/l to above 30 nmol/l.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 65), ('INCOMPLETE_EVIDENCE', 68), ('SUPERFICIAL_RELATIONSHIP', 95), ('QUESTION_ANSWERED_BY_THIS_WORK', 169), ('QUESTION_ANSWERED_BY_THIS_WORK', 176), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 187), ('SUPERFICIAL_RELATIONSHIP', 299)]	9	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 148, '25(OH'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D')]
S165-PMC4302429	PMC4302429	1/2015	S165-PMC4302429	['the concentration of the biologically active form of Vitamin D, 1,25(Oh)2D, is DEPENDENT on the Serum Vitamin D (25(Oh)d) concentration, the substrate for Cyp27B1 [13,37].']	[('SUPERFICIAL_RELATIONSHIP', 79)]	1	"[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_66212', ""5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone"", 66, '25(OH)2D'), ('UBERON_0001977', 'blood serum', 96, 'serum'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 113, '25(OH'), ('PR_000006101', 'cytochrome P450 1A1', 155, 'CYP27B1')]"
S96-PMC4417995	PMC4417995	4/2015	S96-PMC4417995	['[44] reported that high Vitamin D values during Pregnancy MIGHT also be harmful with respect to Allergic disease development: children whose mothers had a 25(Oh)D concentration during Pregnancy of greater than 30\u2009ng/ml had an increased risk of atopic eczema on examination at 9 months compared with children whose mothers had a concentration of less than 12\u2009ng/ml.']	[('INCOMPLETE_EVIDENCE', 58)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('GO_0040011', 'locomotion', 96, 'allergic'), ('CHEBI_63056', 'zinc cation', 155, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 161, 'D'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
S98-PMC4499946	PMC4499946	7/2015	S98-PMC4499946	['our PREVIOUS pharmacokinetic FINDINGS among Pregnant women in dhaka [16,40] HAVE GENERALLY BEEN CONSISTENT with published ESTIMATES of the Vitamin D-to-25(Oh)D dose–response RELATIONSHIP in non-Pregnant Adults (i.e., an APPROXIMATELY 0.7 nmol/l increase in 25(Oh)D at steady state for each 1 μg/day of Vitamin D3[41,42]).']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 76), ('PROBABLE_UNDERSTANDING', 81), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 220)]	8	[('GO_0007565', 'female pregnancy', 44, 'pregnant'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 155, 'OH)D'), ('GO_0007565', 'female pregnancy', 194, 'pregnant'), ('UBERON_0007023', 'adult organism', 203, 'adults'), ('CHEBI_63056', 'zinc cation', 257, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_33279', 'vitamin D5', 302, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 302, 'vitamin D3')]
S136-PMC4811441	PMC4811441	3/2016	S136-PMC4811441	['also, an increase in 25(Oh)D ≥30 nmol/l was not associated with Pregnancy-induced hypertension.10.1371/journal.pone.0152198.t004\n\ncaption (table-wrap): table 4\nbivariable and multivariable logistic regression analysis of the DETERMINANTS of Pregnancy-induced hypertension.bivariablemultivariableabor95% cipbor95% ciplowerupperlowerupper25(Oh)D t10.0081.0081.0011.0140.0240.0021.0020.9931.0100.709obesity t10.3661.4430.8972.3210.131-0.1690.8440.4641.5380.844nulliparity0.3611.4351.0391.9830.0290.2051.2280.8541.7650.269excessive gwg0.4731.6041.1462.2460.0060.3631.4380.9952.0780.054preexisting medical condition t10.6321.8810.8764.0400.1050.0891.0930.4542.6290.842assisted reproduction0.1821.2000.7881.8280.3950.0841.0880.6561.8030.745tobacco use t1-0.6330.5310.2161.3080.169-0.4470.6400.2621.5630.327height0.0541.0551.0291.083<0.0010.0351.0351.0051.0660.021age ≥40 years t1-0.1410.8680.3732.0240.744-0.1920.8250.3122.1840.699dbp t10.0871.0911.0691.114<0.0010.0881.0921.0671.117<0.001\n25(Oh)d = 25-Hydroxyvitamin D, t1 = first trimester, gwg = Gestational weight gain, dbp = diastolic Blood pressure,\ndichotomous: age ≥40 years, obesity, nulliparity, excessive gwg, preexisting medical condition and assisted reproduction\na.adjusted for multifetal Pregnancy, baseline employment status, Gestational age at t1, month of Conception and northern european country of Birth\n\ndiscussion\nthese results are the primary outcome of the gravid study–TO OUR KNOWLEDGE the FIRST STUDY reporting on the RELATIONSHIP between longitudinal Vitamin D status and its RELATION to pe and Gestational bp trajectory.']	[('SUPERFICIAL_RELATIONSHIP', 225), ('PROBABLE_UNDERSTANDING', 1438), ('INCOMPLETE_EVIDENCE', 1459), ('SUPERFICIAL_RELATIONSHIP', 1488), ('SUPERFICIAL_RELATIONSHIP', 1547)]	5	[('CHEBI_71657', 'versiconol acetate', 21, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 21, '25(OH)D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy'), ('CHEBI_33010', 'chromide(1-)', 338, '(OH)D'), ('CHEBI_63056', 'zinc cation', 984, '25(OH'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 994, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1043, 'gestational'), ('UBERON_0000178', 'blood', 1084, 'blood'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1286, 'gestational'), ('GO_0007620', 'copulation', 1318, 'conception'), ('GO_0007567', 'parturition', 1362, 'birth'), ('CHEBI_27300', 'vitamin D', 1522, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1566, 'gestational')]
S117-PMC4897157	PMC4897157	5/2016	S117-PMC4897157	['in a Birth cohort study cord Blood 25(Oh)-Vitamin D deficiency was ASSOCIATED with INCREASED RISK of recurrent troublesome Lung symptoms till age 7 years, BUT SHOWED no association with Respiratory infection, asthma, or rhinitis21).']	[('SUPERFICIAL_RELATIONSHIP', 67), ('IMPORTANT_CONSIDERATION', 83), ('ANOMALY_CURIOUS_FINDING', 155), ('INCOMPLETE_EVIDENCE', 159)]	4	[('GO_0007567', 'parturition', 5, 'birth'), ('UBERON_0000178', 'blood', 29, 'blood'), ('CHEBI_63056', 'zinc cation', 35, '25(OH'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0002048', 'lung', 123, 'lung'), ('UBERON_0001004', 'respiratory system', 186, 'respiratory')]
S74-PMC5045784	PMC5045784	10/2016	S74-PMC5045784	['fetal and newborn concentrations of 25(Oh)D DEPEND ON and CORRELATE with maternal Serum levels AS the fetus has no endogenous production of 25(Oh)d and DEPENDS on transplacental transfer.28THIS occurs MAINLY in the third trimester and THEREFORE, as we and others PREVIOUSLY REPORTED, preterm infants are at INCREASED RISK of Vitamin D deficiency.10,29our PRIOR STUDY DEMONSTRATED that Birth before 32 completed weeks of Gestation is an INDEPENDENT RISK FACTOR for low 25(Oh)d levels at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 152), ('PROBABLE_UNDERSTANDING', 187), ('PROBABLE_UNDERSTANDING', 201), ('PROBABLE_UNDERSTANDING', 235), ('INCOMPLETE_EVIDENCE', 263), ('IMPORTANT_CONSIDERATION', 307), ('INCOMPLETE_EVIDENCE', 355), ('INCOMPLETE_EVIDENCE', 367), ('SUPERFICIAL_RELATIONSHIP', 436), ('SUPERFICIAL_RELATIONSHIP', 448)]	13	[('CHEBI_71657', 'versiconol acetate', 36, '25(OH)D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_63056', 'zinc cation', 140, '25(OH'), ('CHEBI_27300', 'vitamin D', 325, 'vitamin D'), ('GO_0007567', 'parturition', 385, 'birth'), ('GO_0007565', 'female pregnancy', 420, 'gestation'), ('CHEBI_30778', 'gallic acid', 468, '25(OH)'), ('GO_0007567', 'parturition', 486, 'birth')]
S177-PMC5129897	PMC5129897	10/2016	S177-PMC5129897	['for example, 50% of the clinical trials with baseline 25(Oh)D concentration <50\xa0nmol/l FOUND beneficial EFFECTS of Vitamin D on BIOMARKERS of inflammation, WHEREAS ONLY 26% of those with higher baseline 25(Oh)D concentrations did.3the DIFFERENT results with respect to baseline 25(Oh)D concentration MAY BE DUE TO the LIMITED accuracy of clinical trials but COULD also be DUE TO CONSIDERABLY less BENEFIT for those with 25(Oh)D concentrations above 50\xa0nmol/l.']	[('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 128), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156), ('ANOMALY_CURIOUS_FINDING', 156), ('ANOMALY_CURIOUS_FINDING', 164), ('INCOMPLETE_EVIDENCE', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('INCOMPLETE_EVIDENCE', 300), ('PROBLEM_COMPLICATION', 307), ('INCOMPLETE_EVIDENCE', 318), ('INCOMPLETE_EVIDENCE', 358), ('PROBLEM_COMPLICATION', 372), ('ANOMALY_CURIOUS_FINDING', 379), ('IMPORTANT_CONSIDERATION', 397)]	15	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 54, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 203, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 203, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 278, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 284, 'D'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D')]
S112-PMC5155676	PMC5155676	12/2016	S112-PMC5155676	['HOWEVER, it is NOTABLE that there were marked DIFFERENCES in baseline 25(Oh)D concentrations between these investigations, and we OBSERVED that initial 25(Oh)D status was positively ASSOCIATED with both the LIKELIHOOD of achieving Vitamin D replete status and absolute 25(Oh)D status at 34 weeks of Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 46), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 182), ('PROBABLE_UNDERSTANDING', 207)]	7	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 76, 'D'), ('CHEBI_63056', 'zinc cation', 152, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('GO_0007565', 'female pregnancy', 299, 'gestation')]
S77-PMC5418719	PMC5418719	5/2017	S77-PMC5418719	['caption (table-wrap): table 2\n\nVitamin D statusvariablecord 25(Oh)D concentrations <10\xa0ng/mlcord 25(Oh)D concentrations ≥10\xa0ng/ml p at Birth\u2003n2029\u2003Serum 25(Oh)D levels8.3\u2009±\u20091.921.4\u2009±\u20098.5<0.001\u2003Vitamin D sufficiency (>30\xa0ng/ml)0 (0%)5 (17%)0.0732\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1318\u2003Serum 25(Oh)d levels15.3\u2009±\u200910.124.1\u2009±\u20099.30.05\u2003Vitamin D sufficiency (>30\xa0ng/ml)3 (23%)4 (22%)1.0036\u2009±\u20091\xa0weeks Postmenstrual age\u2003n1726\u2003Serum 25(Oh)D levels43.1\u2009±\u200920.357.7\u2009±\u200921.90.03\u2003Vitamin D sufficiency (>30\xa0ng/ml)11 (65%)23 (88%)0.12\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ntable\xa03presents the levels of Serum calcium, Phosphorous, alkaline phosphatase level at Birth, 32\u2009±\u20091\xa0weeks pma, and 36\u2009±\u20091\xa0weeks pma as MARKERS of Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 710)]	1	[('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('GO_0007567', 'parturition', 135, 'birth'), ('UBERON_0001977', 'blood serum', 147, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 153, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 153, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 193, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 256, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 280, 'Serum'), ('CHEBI_63056', 'zinc cation', 286, '25(OH'), ('CHEBI_28384', 'vitamin K', 326, 'Vitamin D'), ('GO_0008283', 'cell proliferation', 390, 'postmenstrual'), ('UBERON_0001977', 'blood serum', 414, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 420, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 420, '25(OH)D'), ('CHEBI_28384', 'vitamin K', 461, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 603, 'serum'), ('CHEBI_30207', 'phosphorus(.)', 618, 'phosphorous'), ('GO_0007567', 'parturition', 661, 'birth'), ('CHEBI_27300', 'vitamin D', 721, 'vitamin D')]
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	"[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', ""3-iodo-4-aminobenzyl-5'-N-methylcarboxamidoadenosine"", 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]"
S5-PMC5537904	PMC5537904	7/2017	S5-PMC5537904	['non-hispanic white race, lower Pre-Pregnancy bmi, higher Prenatal Vitamin D intake, and summer Births were ASSOCIATED with higher Cord Blood 25(Oh)D. higher 25(Oh)D was ASSOCIATED with lower Birthweight ( β = –6.22, p = 0.02), but as maternal bmi increased, this ASSOCIATION became increasingly positive in direction and magnitude ( β = 1.05, p = 0.04).']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 169), ('SUPERFICIAL_RELATIONSHIP', 263)]	3	[('GO_0007568', 'aging', 31, 'pre'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007567', 'parturition', 95, 'births'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('UBERON_0000178', 'blood', 135, 'blood'), ('CHEBI_63056', 'zinc cation', 141, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 147, 'D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 157, '25(OH ... D'), ('GO_0007596', 'blood coagulation', 191, 'birthweight')]
S129-PMC5546866	PMC5546866	8/2017	S129-PMC5546866	['the Dhcr7 Gene encodes 7-Dhc reductase, which converts 7-Dhc back to Cholesterol, thereby reducing the availability of 7-Dhc for conversion to previtamin d. the ASSOCIATION of this Snp with only baseline 25(Oh)D is biologically CONSISTENT with the NOTION that the relative proportion of 25(Oh)D obtained from Vitamin D Biosynthesis in the skin AS OPPOSED TO dietary intake is lower following supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 161), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 248), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344)]	4	[('PR_000006474', 'ATP-dependent RNA helicase A', 4, 'DHCR7'), ('SO_0000704', 'gene', 10, 'gene'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 23, '7-DHC'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 55, '7-DHC'), ('CHEBI_16113', 'cholesterol', 69, 'cholesterol'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 119, '7-DHC'), ('SO_0000694', 'SNP', 181, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 204, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 287, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 293, 'D'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 309, 'vitamin D biosynthesis')]
S113-PMC5659607	PMC5659607	10/2017	S113-PMC5659607	['Lower Respiratory Tract infections (lrti) are analyzed by poisson regression model.Vitamin D vs.placeboipdor (95% ci)asthma/ recurrent wheeze0.75 (0.57–0.97)p = 0.03total Ige > median0.93 (0.73–1.18)p = 0.43specific Ige > 0.35ku/l1.05 (0.77–1.43)p = 0.78eczema0.91 (0.71–1.18)p = 0.47lrti0.92 (0.75–1.14)p = 0.44\n\ndiscussion\nin THIS combined analysis of the two largest rcts to date of Vitamin D supplementation during Pregnancy, we SHOWED that the supplementation resulted in a significant and clinically IMPORTANT 26% reduced risk of asthma/recurrent wheeze in the offspring until age 3, with a more pronounced 46% reduced risk if the women had 25(Oh)d level ≥30ng/ml at trial entry.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 328), ('INCOMPLETE_EVIDENCE', 433), ('IMPORTANT_CONSIDERATION', 506)]	3	[('UBERON_0004905', 'articulation', 0, 'Lower respiratory tract'), ('CHEBI_28384', 'vitamin K', 83, 'Vitamin D'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 171, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 216, 'IgE'), ('CHEBI_27300', 'vitamin D', 386, 'vitamin D'), ('GO_0007565', 'female pregnancy', 419, 'pregnancy'), ('CHEBI_63056', 'zinc cation', 647, '25(OH')]
S89-PMC5679631	PMC5679631	11/2017	S89-PMC5679631	['use of multivitamin supplements containing Vitamin D and maternal obesity were ASSOCIATED with maternal 25(Oh)D level during both low and high seasons, WHILE recruitment group was significantly ASSOCIATED with 25(Oh)D concentration ONLY during the high season.10.1371/journal.pone.0188011.t002\n\ncaption (table-wrap): table 2\nmean maternal 25(Oh)D concentration according to season of Blood sampling and use of multivitamin supplements containing Vitamin D.Blood sampling in high season of cutaneous Vitamin D productionblood sampling in low season of cutaneous Vitamin D production maternal use of multivitamin supplement containing Vitamin Dmaternal Plasma 25(Oh)d nmol/lmaternal Plasma 25(Oh)D nmol/l no (mean (sd))45.2 (17.0)30.1 (13.5)yes (mean (sd))53.3 (17.8)40.9 (16.1)p value&p = 0.000p = 0.000model # beta (95% ci)beta (95% ci) constant52.7 (47.7, 57.7)34.6 (29.5, 39.7)maternal use of multivitamin supplement containing Vitamin D (yes vs .']	[('SUPERFICIAL_RELATIONSHIP', 79), ('ANOMALY_CURIOUS_FINDING', 152), ('SUPERFICIAL_RELATIONSHIP', 194), ('INCOMPLETE_EVIDENCE', 232)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 104, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 210, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 339, '25 ... OH ... D'), ('UBERON_0000178', 'blood', 384, 'blood'), ('CHEBI_27300', 'vitamin D', 446, 'vitamin D'), ('UBERON_0000178', 'blood', 456, 'Blood'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_61716', 'alpha-Kdo-CH2OH-(2->4)-alpha-Kdo', 633, 'vitamin DMaternal'), ('UBERON_0001969', 'blood plasma', 651, 'Plasma'), ('CHEBI_63056', 'zinc cation', 658, '25(OH'), ('UBERON_0001969', 'blood plasma', 681, 'Plasma'), ('CHEBI_71657', 'versiconol acetate', 688, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 930, 'vitamin D')]
S46-PMC5706533	PMC5706533	11/2017	S46-PMC5706533	['when multiple comparisons from the same trial were included in the same meta-analysis, we divided the control group sample size corresponding to each comparison by the number of intervention arms to avoid double counting participants.14\nwe conducted subgroup meta-analyses according to a priori defined sources of potential clinical and methodological heterogeneity17: control arm type (Placebo versus Vitamin D containing active control); dosing frequency (regular versus bolus); baseline Vitamin D status categorised as low (mean 25(Oh)D <30 nmol/l) versus sufficient (≥30 nmol/l), based on maternal mean 25(Oh)D in the control group at enrolment (“initial baseline”) or at/near delivery (“modified baseline,” which THEORETICALLY takes into account the effect of active control supplementation); intervention dose (among regular dose trials), defined as low (<2000 iu/day) versus high (≥2000 iu/day).']	[('INCOMPLETE_EVIDENCE', 718)]	1	[('CHEBI_26130', 'biological pigment', 387, 'placebo'), ('CHEBI_27300', 'vitamin D', 402, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 532, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 538, 'D'), ('CHEBI_71657', 'versiconol acetate', 607, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 613, 'D')]
S114-PMC5706533	PMC5706533	11/2017	S114-PMC5706533	['in a post hoc analysis of the EFFECT on Birth weight that took into account both effective dose and baseline Vitamin D status, there was a significant dose-response effect in trials in which mean baseline 25(Oh)D was 30-50 nmol/l but no association in trials with mean 25(Oh)d <30 nmol/l (fig s29 in appendix 10).']	[('SUPERFICIAL_RELATIONSHIP', 30)]	1	[('GO_0007567', 'parturition', 40, 'birth'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 269, '25(OH')]
S101-PMC5827025	PMC5827025	2/2018	S101-PMC5827025	['follow-up, SEVERAL randomized TRIAL of Vitamin D supplementation FOUND that the rate of Preterm Delivery is significant more lower in Pregnant women with Serum 25(Oh)D ≥40\u2009ng/ml COMPARED TO those with Serum 25(Oh)D ≤20\u2009ng/ml, SUGGESTING higher 25(Oh)D concentration was ASSOCIATED with an decreased risk of Preterm Delivery35–38.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 270)]	5	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'preterm'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_63056', 'zinc cation', 160, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 166, 'D'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 210, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 213, 'D'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('GO_0007565', 'female pregnancy', 307, 'preterm'), ('GO_0008219', 'cell death', 315, 'delivery35')]
S88-PMC5941617	PMC5941617	5/2018	S88-PMC5941617	['[84]oct 201310810011–14\xa0yearssalerno (40°n)45.4 (overweight or obese)0aclaaa83.3bmi\ncl chemiluminescence, ria radioimmunoassay, tm tandem mass, bmi body mass index\nadata not reported\nbi 25(Oh)D3Tertile: 11.5\u2009±\u20094.2\xa0years; ii 25(oh)d3tertile 11.2\u2009±\u20094.3\xa0years; iii 25(Oh)d3tertile 11.0\u2009±\u20094.0\xa0years (median\u2009±\u2009interquartile range)\ncmean\u2009±\u2009standard error of mean\ndchildren AFFECTED by growth hormone deficiency\n\nsources of Vitamin D and dietary reference values\nmost of the Vitamin D we synthesize (90%) starts with skin exposure to ultraviolet b radiation from the sun.']	[('SUPERFICIAL_RELATIONSHIP', 367)]	1	[('CHEBI_52182', 'meso-bromoporphyrin', 186, '25(OH)D3tertile'), ('CHEBI_63056', 'zinc cation', 262, '25(OH'), ('CHEBI_27300', 'vitamin D', 417, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 468, 'vitamin D')]
S435-PMC5941617	PMC5941617	5/2018	S435-PMC5941617	['a recent meta-analysis SHOWED that patients with crohn’s disease ( n \u2009=\u2009129808, age 11–48\xa0years) had lower Serum 25(Oh)D concentrations compared with healthy controls, with an overall prevalence of Vitamin D deficiency [25(Oh)D\u2009<\u2009\xa020\xa0ng/ml] of 57.7% and an inverse CORRELATION between Serum 25(Oh)D levels and the severity of disease [399].']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 265)]	2	[('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_63056', 'zinc cation', 113, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 119, 'D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('UBERON_0001977', 'blood serum', 285, 'serum'), ('CHEBI_71657', 'versiconol acetate', 291, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 291, '25(OH ... D')]
